Sector
PharmaceuticalsOpen
₹180.01Prev. Close
₹185.37Turnover(Lac.)
₹958.88Day's High
₹189.5Day's Low
₹18052 Week's High
₹197.0552 Week's Low
₹97.45Book Value
₹27.48Face Value
₹1Mkt Cap (₹ Cr.)
8,577.94P/E
62.76EPS
2.95Divi. Yield
0.322 Aug 2023
12:00 AM
AGM
Announcement Date: 02 Aug, 2023
13 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 45.32 | 134.03 | 40.93 | 40.93 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,066.01 | 650.64 | 558.79 | 464.69 |
Net Worth | 1,111.33 | 784.67 | 599.72 | 505.62 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 599.54 | 433.41 | 294.66 | 215.83 |
yoy growth (%) | 38.33 | 47.08 | 36.51 | -39.73 |
Raw materials | -337.91 | -243.03 | -169.34 | -112.37 |
As % of sales | 56.36 | 56.07 | 57.47 | 52.06 |
Employee costs | -54.63 | -48.5 | -45.85 | -39.77 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 124.32 | 52.72 | 16.65 | 11.94 |
Depreciation | -15.19 | -11.64 | -12.25 | -15 |
Tax paid | -25.94 | -14.82 | -4.22 | -0.4 |
Working capital | 82.13 | -10.16 | 7.89 | 46.78 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 38.33 | 47.08 | 36.51 | -39.73 |
Op profit growth | 59.06 | 96.13 | 48.84 | -76.42 |
EBIT growth | 116.05 | 146.78 | 47.96 | -83.19 |
Net profit growth | 159.55 | 205 | 7.64 | -83.84 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 2,177.41 | 1,852.14 | 1,490.84 | 1,376.18 | 1,134.21 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 2,177.41 | 1,852.14 | 1,490.84 | 1,376.18 | 1,134.21 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 50.42 | 59.31 | 41.85 | 6.69 | 0.33 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Mark Saldanha
Company Sec. & Compli. Officer
Harshavardhan Panigrahi
Non-Exec. & Independent Dir.
Seetharama Raju Buddharaju
Whole-time Director
Sandra Saldanha
Non-Exec. & Independent Dir.
Digant Mahesh Parikh
Whole-time Director
Varddhman Vikramaditya Jain
Non-Exec. & Independent Dir.
Abhinna Sundar Mohanty
Director
Sunny Sharma
Independent Director
Shailaja Vardhan
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Marksans Pharma Ltd
Summary
Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982. Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005. The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Companys research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai.In 2004-05, the Company amalgamated with M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited) pursuant to High Court order dated 19th August, 2005. As provided in the approved Scheme of Amalgamation, necessary shares were issued to the shareholders of the M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited). The Company acquired majority stake in Nova Pharmaceuticals Australasia Private Limited in 2005; further, it acquired two companies, Bell Sons & Company (Druggists) Limited and Relonchem Limited in the UK in 2008. The Company received first ANDA approval in the USA in 2011. It acquired Time-Cap Laboratories Inc. in the US in 2015. The Company launched the CNS-Cerebella division in FY 2017-18. It launched soft gelatin capsules, a niche category, Launched two products and received CRL for 4 ANDAs for approval with the USFDA. The Company commissioned a new R&D center at Navi Mumbai, apart from one in Goa in 2019-20. The Company acquired the bus
Read More
What is the Marksans Pharma Ltd share price today?
The Marksans Pharma Ltd shares price on N/A is Rs.₹188.55 today.
What is the Market Cap of Marksans Pharma Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Marksans Pharma Ltd is ₹8544.40 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Marksans Pharma Ltd?
The PE and PB ratios of Marksans Pharma Ltd is 62.76 and 6.86 as of 22 Jul ‘24
What is the 52 Week High and Low of Marksans Pharma Ltd?
The 52-week high/low is the highest and lowest price at which a Marksans Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Marksans Pharma Ltd is ₹93.85 and ₹197.25 as of 22 Jul ‘24
What is the CAGR of Marksans Pharma Ltd?
Marksans Pharma Ltd's CAGR for 5 Years at 60.84%, 3 Years at 27.92%, 1 Year at 67.31%, 6 Month at 17.22%, 3 Month at 6.16% and 1 Month at 17.29%.
What is the shareholding pattern of Marksans Pharma Ltd?
The shareholding pattern of Marksans Pharma Ltd is as follows:
Promoters - 43.87 %
Institutions - 22.34 %
Public - 33.78 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
